Revvity Inc. $RVTY Shares Acquired by State Street Corp

Key Points

• State Street increased its Revvity stake by 0.8% in the second quarter, owning 4.34 million shares valued at approximately $483.2 million, or 3.89% of the company. Institutional investors collectively own 86.65% of Revvity.
• Revvity insiders sold 9,046 shares worth about $1.28 million over the past 90 days, while insiders retain just 0.85% of the stock.
• Analyst sentiment remains cautious, with four Buy ratings and fourteen Holds and a consensus price target of $116.57. The company nevertheless exceeded quarterly earnings expectations, reporting $1.41 EPS and $729.7 million in revenue, and declared a $0.07 quarterly dividend.

State Street Corp boosted its stake in Revvity Inc. (NYSE:RVTY - Free Report) by 0.8% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,342,739 shares of the company's stock after acquiring an additional 32,426 shares during the period. State Street Corp owned 3.89% of Revvity worth $483,173,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio acquired a new stake in shares of Revvity during the second quarter worth $3,845,000. Bank of New York Mellon Corp purchased a new position in Revvity during the 2nd quarter worth $78,766,000. Tocqueville Asset Management L.P. purchased a new position in Revvity during the 2nd quarter worth $4,791,000. The Manufacturers Life Insurance Company lifted its stake in shares of Revvity by 5.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 368,938 shares of the company's stock worth $41,048,000 after acquiring an additional 20,278 shares during the period. Finally, California State Teachers Retirement System lifted its stake in shares of Revvity by 19.8% in the 1st quarter. California State Teachers Retirement System now owns 133,809 shares of the company's stock worth $11,723,000 after acquiring an additional 22,075 shares during the period. 86.65% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Revvity

In other news, insider Maxwell Krakowiak sold 1,631 shares of Revvity stock in a transaction on Monday, September 21st. The stock was sold at an average price of $144.53, for a total transaction of $235,728.43. Following the completion of the transaction, the insider owned 14,781 shares of the company's stock, valued at $2,136,297.93. The trade was a 9.94% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Tajinder S. Vohra sold 7,330 shares of Revvity stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total value of $1,032,650.40. Following the transaction, the insider directly owned 6,635 shares of the company's stock, valued at $934,738.80. This trade represents a 52.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 9,046 shares of company stock valued at $1,277,685. 0.85% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of Revvity from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, July 30th. KeyCorp raised their price objective on shares of Revvity from $125.00 to $165.00 and gave the company an "overweight" rating in a research report on Friday, September 4th. Zacks Research raised Revvity from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 4th. UBS Group assumed coverage on Revvity in a research report on Wednesday, September 9th. They set a "neutral" rating and a $140.00 target price on the stock. Finally, Royal Bank Of Canada assumed coverage on Revvity in a research note on Tuesday, September 1st. They set a "sector perform" rating and a $135.00 target price for the company. Four equities research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $116.57.

Revvity Stock Down 0.8%

Shares of NYSE RVTY opened at $142.23 on Thursday. The company has a quick ratio of 1.50, a current ratio of 1.80 and a debt-to-equity ratio of 0.36. Revvity Inc. has a 52 week low of $81.22 and a 52 week high of $149.52. The firm has a 50-day moving average price of $122.53 and a 200 day moving average price of $105.76. The stock has a market capitalization of $15.87 billion, a price-to-earnings ratio of 67.73, a price-to-earnings-growth ratio of 2.61 and a beta of 1.09.

Revvity (NYSE:RVTY - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, topping the consensus estimate of $1.21 by $0.20. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The company had revenue of $729.69 million for the quarter, compared to analyst estimates of $702.96 million. During the same period in the prior year, the business posted $1.18 earnings per share. The firm's revenue for the quarter was down 1.3% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts anticipate that Revvity Inc. will post 5.36 EPS for the current fiscal year.

Revvity Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be issued a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, October 23rd. This represents a $0.28 annualized dividend and a yield of 0.2%. Revvity's payout ratio is currently 13.33%.

About Revvity

Revvity, Inc is a life sciences and diagnostics company that provides technologies, products and services used by researchers, healthcare professionals and laboratories. Its offerings support applications across genomics, proteomics, cellular analysis, drug discovery, disease research and laboratory testing.

The company develops and supplies scientific instruments, reagents, consumables, software and workflow solutions. Its portfolio includes platforms for genetic and molecular analysis, imaging, high-throughput screening, biomarker research and single-cell analysis, as well as laboratory solutions used in areas such as reproductive health and newborn screening.

Revvity was established in 2023 following the separation of PerkinElmer's Applied, Food and Enterprise Services businesses from its Precision Diagnostics operations.

Want to see what other hedge funds are holding RVTY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revvity Inc. (NYSE:RVTY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.